420 related articles for article (PubMed ID: 23329394)
1. Targeting the B7 family of co-stimulatory molecules: successes and challenges.
Podojil JR; Miller SD
BioDrugs; 2013 Feb; 27(1):1-13. PubMed ID: 23329394
[TBL] [Abstract][Full Text] [Related]
2. Intact B7-H3 signaling promotes allograft prolongation through preferential suppression of Th1 effector responses.
Ueno T; Yeung MY; McGrath M; Yang S; Zaman N; Snawder B; Padera RF; Magee CN; Gorbatov R; Hashiguchi M; Azuma M; Freeman GJ; Sayegh MH; Najafian N
Eur J Immunol; 2012 Sep; 42(9):2343-53. PubMed ID: 22733595
[TBL] [Abstract][Full Text] [Related]
3. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice.
Li J; Semple K; Suh WK; Liu C; Chen F; Blazar BR; Yu XZ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):962-9. PubMed ID: 21447398
[TBL] [Abstract][Full Text] [Related]
4. The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis.
Wiendl H; Neuhaus O; Mehling M; Wintterle S; Schreiner B; Mitsdoerffer M; Wienhold W; Weissert R; Wessels J; Hartung HP; Weller M; Tolosa E; Melms A
J Neuroimmunol; 2003 Jul; 140(1-2):177-87. PubMed ID: 12864987
[TBL] [Abstract][Full Text] [Related]
5. Targeting T cell costimulation in autoimmune disease.
Stuart RW; Racke MK
Expert Opin Ther Targets; 2002 Jun; 6(3):275-89. PubMed ID: 12223069
[TBL] [Abstract][Full Text] [Related]
6. CTLA4-Ig-Based Bifunctional Costimulation Inhibitor Blocks CD28 and ICOS Signaling to Prevent T Cell Priming and Effector Function.
Goenka R; Xu Z; Samayoa J; Banach D; Beam C; Bose S; Dooner G; Forsyth CM; Lu X; Medina L; Sadhukhan R; Sielaff B; Sousa S; Tao Q; Touw D; Wu F; Kingsbury GA; Akamatsu Y
J Immunol; 2021 Mar; 206(5):1102-1113. PubMed ID: 33495237
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of CTLA-4-Ig in tolerance induction.
Alegre ML; Fallarino F
Curr Pharm Des; 2006; 12(2):149-60. PubMed ID: 16454732
[TBL] [Abstract][Full Text] [Related]
8. The role of co-stimulation in airway inflammation.
Djukanovic R
Clin Exp Allergy; 2000 Jun; 30 Suppl 1():46-50. PubMed ID: 10849475
[TBL] [Abstract][Full Text] [Related]
9. The B7 family revisited.
Greenwald RJ; Freeman GJ; Sharpe AH
Annu Rev Immunol; 2005; 23():515-48. PubMed ID: 15771580
[TBL] [Abstract][Full Text] [Related]
10. CTLA4-Ig: a novel immunosuppressive agent.
Najafian N; Sayegh MH
Expert Opin Investig Drugs; 2000 Sep; 9(9):2147-57. PubMed ID: 11060799
[TBL] [Abstract][Full Text] [Related]
11. CD28/B7 costimulation: a review.
Greenfield EA; Nguyen KA; Kuchroo VK
Crit Rev Immunol; 1998; 18(5):389-418. PubMed ID: 9784967
[TBL] [Abstract][Full Text] [Related]
12. Blocking inducible co-stimulator in the absence of CD28 impairs Th1 and CD25+ regulatory T cells in murine colitis.
de Jong YP; Rietdijk ST; Faubion WA; Abadia-Molina AC; Clarke K; Mizoguchi E; Tian J; Delaney T; Manning S; Gutierrez-Ramos JC; Bhan AK; Coyle AJ; Terhorst C
Int Immunol; 2004 Feb; 16(2):205-13. PubMed ID: 14734605
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28.
Lin H; Rathmell JC; Gray GS; Thompson CB; Leiden JM; Alegre ML
J Exp Med; 1998 Jul; 188(1):199-204. PubMed ID: 9653096
[TBL] [Abstract][Full Text] [Related]
14. Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation.
Gonzalo JA; Delaney T; Corcoran J; Goodearl A; Gutierrez-Ramos JC; Coyle AJ
J Immunol; 2001 Jan; 166(1):1-5. PubMed ID: 11123268
[TBL] [Abstract][Full Text] [Related]
15. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses.
Coyle AJ; Lehar S; Lloyd C; Tian J; Delaney T; Manning S; Nguyen T; Burwell T; Schneider H; Gonzalo JA; Gosselin M; Owen LR; Rudd CE; Gutierrez-Ramos JC
Immunity; 2000 Jul; 13(1):95-105. PubMed ID: 10933398
[TBL] [Abstract][Full Text] [Related]
16. Pharmacotherapy: concepts of pathogenesis and emerging treatments. Co-stimulation and T cells as therapeutic targets.
Gizinski AM; Fox DA; Sarkar S
Best Pract Res Clin Rheumatol; 2010 Aug; 24(4):463-77. PubMed ID: 20732645
[TBL] [Abstract][Full Text] [Related]
17. The Concordant Disruption of B7/CD28 Immune Regulators Predicts the Prognosis of Oral Carcinomas.
Chang SR; Chou CH; Liu CJ; Lin YC; Tu HF; Chang KW; Lin SC
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983005
[TBL] [Abstract][Full Text] [Related]
18. Involvement of CD28/CTLA4-B7 costimulatory pathway in the development of lymphadenopathy and splenomegaly in MRL/lpr mice.
Takiguchi M; Murakami M; Nakagawa I; Rashid MM; Tosa N; Chikuma S; Hashimoto A; Uede T
J Vet Med Sci; 2000 Jan; 62(1):29-36. PubMed ID: 10676886
[TBL] [Abstract][Full Text] [Related]
19. Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept.
Fiocco U; Sfriso P; Oliviero F; Pagnin E; Scagliori E; Campana C; Dainese S; Cozzi L; Punzi L
Autoimmun Rev; 2008 Oct; 8(1):76-82. PubMed ID: 18718877
[TBL] [Abstract][Full Text] [Related]
20. The immune response induced in vivo by dendritic cells is dependent on B7-1 or B7-2, but the inhibition of both signals does not lead to tolerance.
Lespagnard L; Mettens P; De Smedt T; Bazin H; Urbain J; Leo O; Moser M
Int Immunol; 1998 Mar; 10(3):295-304. PubMed ID: 9576617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
